Table 3.
Comparison of symptoms after the second dose in patients with IBD (study) group vs. healthy participants (control) group.
| Characteristic | Study group, N = 102 a | Control group, N = 102 a | P b |
|---|---|---|---|
| Age_in years | 34 (25, 41) | 33 (25, 45) | |
| Gender | |||
| Female | 43 (42%) | 49 (48%) | |
| Male | 59 (58%) | 53 (52%) | |
| Injection site | |||
| Pain | 32 (31%) | 50 (49%) | 0.010 |
| Redness | 4 (3.9%) | 15 (15%) | 0.008 |
| Swelling | 3 (2.9%) | 29 (28%) | <0.001 |
| Systemic AEs | |||
| Tiredness | 25 (24%) | 49 (48%) | <0.001 |
| Headache | 21 (20%) | 35 (34%) | 0.001 |
| Muscle pain | 16 (15%) | 34 (33%) | <0.001 |
| Chills | 9 (8.8%) | 19 (19%) | 0.042 |
| Fever | 20 (20%) | 26 (25%) | 0.3 |
| Nausea | 2 (2.0%) | 14 (14%) | 0.002 |
| Joint pain | 4 (3.9%) | 20 (20%) | <0.001 |
a
Median (IQR) or frequency (%).
b
Wilcoxon rank sum test; Pearson's Chi-squared test.